碧迪医疗计划出售其生命科学业务,已与赛默飞世尔、丹纳赫等展开谈判。该业务去年收入52亿美元,分拆旨在加强战略聚焦,增加增长投资,为股东创造更高价值。据报道,该部门估值可能达215亿美元。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.